Clinical outcome and risk factors related to extended-spectrum beta-lactamase-producing Klebsiella spp. infection among hospitalized patients

Memorias do Instituto Oswaldo Cruz

Volumn 101, Issue 4, 2006, Pages 415-421

  Bellíssimo Rodrigues, Fernando ^a   Gomes, Ana Carolina Frade ^a   Passos, Afonso Dinis Costa ^a   Achcar, Jorge Alberto ^a   Perdona, Gleici Da Silva Castro ^a   Martinez, Roberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Clinical outcome; Extended spectrum beta lactamase; Klebsiella spp.; Risk factors

Indexed keywords

BACILLI (CLASS); KLEBSIELLA; NEGIBACTERIA;

EID: 33747086585     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762006000400012     Document Type: Article

References (37)

1. Archibald LK 2004. Gram-negative, hospital-acquired infections: a growing problem. Infect Control Hosp Epidemiol 25: 809-811.
2. Bermejo J, Lesnaberes P, Arnesi N, Gianello M, Notario R, Borda N, Gambande T, Bencomo B 2003. Factores de riesgo asociados a infecciones por Klebsiella pneumoniae. Enferm Infecc Microbiol Clin 21: 72-76.
3. Bland JM, Altman DG 1998. Statistics notes: Bayesians and frequentists. Br Med J 317: 1151.
4. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, Karumudi P, Tolaney P, Quale J 2005. Emergence of KPC-possesing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 49: 3018-3020.
5. Calatayud L, Dominguez C, Ardanuy F, Tubau M, Argerich J, Liñares C, Peña M, Pujol R, Martín R 2005. Simultaneous colonization by different species of extended-spectrum beta-lactamases producing Enterobacteriaceae (ESBL-EB) in ICU patients. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC, p. 331.
6. CDC-Centers for Disease Control and Prevention. 1998. National nosocomial infections surveillance system antimicrobial resistance surveillance report [on line] http://www.cdc.gov/ncidod/hip/NNIS/AR_Surv1198.htm. Accessed 25 April 2004.
7. Chanawong A, M'zali FH, Heritage J, Lulitanond A, Hawkey PM 2001. SHV-12, SHV-5, SHV-2a and VEB-1 extended-spectrum beta-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. J Antimicrob Chemother 48: 839-852.
8. Cofsky R, Vangala K, Haag R, Recco R, Maccario E, Sathe S, Landman D, Mayorga D, Burgonio B, Sepkowitz D, Chapnick E, Hinedi T, Adedeji A, Quale J 2002. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 23: 106-108.
9. Fredman, L. 1996. Bayesian statistical methods. Br Med J 313: 569-570.
10. Garner JS, Jarvis WR, Emori TG, Horau TC, Hughes JM 1988. CDC definitions for nosocomial infections, 1988. Am J Infect Control 16: 128-140.
11. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y 2002. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 34: 1558-1563.
12. Itokazu GS, Quinn JP, Kahan FM 1996. Antimicrobial resistance rates among aerobic Gram-negative bacilli recovered from patients in intensive care units: evaluation of national postmarketing surveillance program. Clin Infect Dis 23: 779-784.
13. Kang C, Kim S, Kim DM, Park WB, Lee KD, Kim HB, Oh M, Kim EC, Choe K 2004. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 25: 860-867.
14. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC 2002. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 46: 1481-91.
15. Knothe H, Shah P, Kremery V, Antal M, Mitsuhashi S 1983. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and S. marcescens. Infection 11: 315-317.
16. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO 2001. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32: 1162-1171.
17. Lee S, Lee ES, Park SY, Kim S, Seo Y, Cho YK 2004. Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 25: 832-837.
18. Lupi O, Campos T, Faria E, Kalab L, Pereira B, Brazil P 2004. Epidemiology of multiresistant K. pneumoniae cases using Serial Temporal Models. Int J Antimicrob Agents 24 (Suppl. II): 145-146.
19. Martínez JA, Almela M, Marco F, López F, Soriano A, Mensa J 2005. Prognostic Factors of Escherichia coli, Klebsiella spp and Proteus mirabilis Bacteremia in the Era of Extended-Spectrum β-lactamase Producing Organisms (ESBL). Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC, p. 332.
20. Martins IS, Lopes GS, Santos IC, Riley LW, Moreira BM 2005. An outbreak of Extended-Spectrum β-lactamase (ESBL)-Producing Klebsiella pneumoniae Infection Among Renal Transplant Patients. In Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC, p. 330.
21. Martone WJ 1991. Year 2000 objectives for preventing nosocomial infections: how do we get there? Am J Med 91: 39-43.
22. Menashe G, Borer A, Yagupsky P, Peled N, Gilad J, Fraser D, Riesenberg K, Schlaefer F 2001. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 33: 188-193.
23. M'zali FH, Chanawong A, Kerr KG, Birkenhead D, Hawkey PM 2000. Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the MAST DD test, the double disc and the E-test ESBL. J Antimicrob Chemother 45: 881-885.
24. NCCLS-National Committee for Clinical Laboratory Standards. 2000. Performance Standards for Antimicrobial Disk Susceptibility Tests, 7th ed., Wayne, PA.
25. Naumovski L, Quinn JP, Miyashiro D, Patel M, Bush K, Singer SB, Graves D, Palskill T, Arwin AM 1992. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 36: 1991-1996.
26. Paterson DL, Ko WC, Mohapatra S 1997. Klebsiella pneumoniae bacteremia: impact of extended-spectrum β-lactamase (ESBL) production in a global study of 216 patients. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC.
27. Paterson DL 2002. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis 34: 1564-1567.
28. Petroni A, Corso A, Melano R, Cacace ML, Bru AM, Rossi A, Galas M 2002. Plasmidic extended-spectrum beta-lactamases in Vibrio Cholerae O1 El Tor isolates in Argentina. Antimicrob Agents Chemother 46: 1462-1468.
29. Piroth L, Aubé H, Doise JM, Vincent-Martin M 1998. Spread of extended-spectrum b-lactamase-producing Klebsiella pneumoniae: are β-lactamase inhibitors of therapeutic value? Clin Infect Dis 27: 76-80.
30. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P 2003. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 41: 3542-3547.
31. Quinteros M, Radice M, Gardella N, Rodriguez MM, Costa N, Korbenfeld D, Couto E, Gutkind G 2003. Extended-spectrum β-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob. Agents Chemother 47: 2864-2867.
32. Rebuck JA, Olsen KM, Fey PD, Langnas NA, Rupp ME 2000. Characterization of an outbreak due to extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 31: 1368-1372.
33. Sader HS, Sampaio JL, Zoccoli C, Jones RN 1999. Results of the 1997 SENTRY antimicrobial surveillance program in three Brazilian medical centers. Braz J Infect Dis 3: 63-79.
34. Saka HA, Egea M, Culasso C, Rollan R, Avaro A, Carvajal L 2003. b-lactamasas de espectro extendido en Klebsiella pneumoniae aisladas en el hospital de niños de Córdoba, Argentina. Rev Argent Microbiol 35: 1-7.
35. Schwaber MJ, Cosgrove SE, Gold HS, Kaye KS, Carmeli Y 2004. Fluorquinolones protective against cephalosporin resistance in Gram-negative nosocomial pathogens. Emerg Infect Dis 10: 94-99.
36. Stone P, Gupta A, Loughrey M, Della-Latta P, Cimiotti J, Larson E, Rubenstein D, Saiman L 2003. Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol 24: 601-606.
37. Weinstein RA 1991. Epidemiology and control of nosocomial infections in adult intensive care units. Am J Med 91: 179-184.